Report for: A Phase 1 Randomized, Double Blind, Placebo Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel (MTN-007)

Title	A Phase 1 Randomized, Double Blind, Placebo Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel (MTN-007)
Published in	PLOS ONE, April 2013
DOI	10.1371/journal.pone.0060147
Pubmed ID	23573238
Authors	Ian Mcgowan, Craig Hoesley, Ross D. Cranston, Philip Andrew, Laura Janocko, James Y. Dai, Alex Carballo-Dieguez, Ratiya Kunjara Na Ayudhya, Jeanna Piper, Florian Hladik, Ken Mayer
Abstract	Rectal microbicides are needed to reduce the risk of HIV acquisition associated with unprotected receptive anal intercourse. The MTN-007 study was designed to assess the safety (general and mucosal), adherence, and acceptability of a new reduced glycerin formulation of tenofovir 1% gel.

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.

Type	Count	As %
Members of the public	7	100%

Mendeley readers

The data shown below were compiled from readership statistics for 95 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Country	Count	As %
United States	2	2%
Unknown	93	98%

Readers by professional status	Count	As %
Researcher	14	15%
Student > Bachelor	13	14%
Student > Master	12	13%
Student > Ph. D. Student	10	11%
Student > Postgraduate	8	8%
Other	13	14%
Unknown	25	26%

Readers by discipline	Count	As %
Medicine and Dentistry	26	27%
Agricultural and Biological Sciences	7	7%
Social Sciences	6	6%
Pharmacology, Toxicology and Pharmaceutical Science	6	6%
Immunology and Microbiology	5	5%
Other	15	16%
Unknown	30	32%

PLOS